1.Bethune G,Bethune D,Ridgway N,et al.Epidermal growth factor receptor (EGFR) in lung cancer:an overview and update.J Thorac Dis 2010;2:48-51.
2.TakedaM,Shimokawa M,Nakamura A,et al.A phaseⅡstudy(WJOG12819L)to assess the efficacy of osimertinib inpatients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first-or second-generation EGFR TKIs and platinum-based chemotherapy.Lung Cancer 2023;177:44-50.
3.Jänne PA,Yang JC,Kim DW,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.N EnglJ Med 2015;372:1689-99.
4.Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel inpatients with non-small-cell lung cancer previously treated with chemotherapy.J Clin Oncol 2004;22:1589-97.
5.Soria JC,Ohe Y,VansteenkisteJ,et al.Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N EnglJ Med 2018;378:113-25.
6.RamalingamSS,VansteenkisteJ,Planchard D,et al.Overall Survival with Osimertinib in Untreated,EGFR-Mutated Advanced NSCLC. N EnglJ Med 2020;382:41-50.
7.Yang JC,Sequist LV,Geater SL,et al.Clinical activity of afatinib inpatients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2,LUX-Lung 3,and LUX-Lung 6.Lancet Oncol 2015;16:830-8.
8.Bar J,PeledN,SchokrpurS,et al. Uncommon EGFR mutations on osimertinib, real-life data(UNICORN study): Updated results,brain efficacy,and resistance mechanisms.J Clin Oncol 2022;40:9109.
9.Chiba M,TogashiY,Bannno E,et al. Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. BMC Cancer 2017;17:281.
10. Grolleau E,Haddad V,Boissière L,et al. Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation.J Thorac Oncol 2019;14:e151-3.
11. Sun R,Hou Z,Zhang Y,et al.Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma.Oncol Lett 2022;24:408.
12. Li BT,Smit EF,Goto Y,et al.Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.N Engl J Med 2022;386:241-51.
13. Li BT,Shen R,Buonocore D,et al.Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers:Results From a Phase Ⅱ Basket Trial.J Clin Oncol 2018;36:2532-7.
14. Marcoux N, GettingerSN, O'Kane G, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas:Clinical Outcomes.J Clin Oncol 2019;37:278-85.
15. Lee C,Liao BC,Subramaniam S,et al. OA09.04 ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumaband Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors. J Thorac Oncol 2023;18:S63.
16. Zhou C,Dong X,Chen G,et al.OA09.06 IMpower151:Phase Ⅲ Study of Atezolizumab+Bevacizumab+ Chemotherapy in 1L Metastatic Nonsquamous NSCLC. J Thorac Oncol 2023;18:S65.
17. Oxnard GR,Thress KS,Alden RS,et al.Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.J Clin Oncol 2016;34:3375-82.
